Cochlear Implantation: A Treatment Option for Severe to Profound Hearing Loss Associated with Fabry Disease

ABSTRACT

Fabry disease (FD) is a rare multisystemic X-linked lysosomal storage disease. The disease affects many systems of the human body. Sensorineural hearing loss, both sudden and progressive, is one of the many clinical manifestations of this disease. There is limited literature published to date discussing hearing- and balance-related symptoms for this patient population. Cochlear implantation has been mentioned in the literature as a possible treatment option but has not been reported in detail. Recently, a patient with Fabry disease was seen at Mayo Clinic in Rochester, Minnesota. He initially presented with complaints of tinnitus. Four months later, he experienced a severe to profound sudden bilateral sensorineural hearing loss and imbalance. He demonstrated 0% word recognition. After receiving sequential bilateral cochlear implants, his word recognition improved significantly. Following management of this patient, a retrospective study of 75 patients seen at Mayo Clinic for FD revealed 56 were either positive for FD or were carriers. Males represented 61% of this population and 39% were females. Two standardized questionnaires were made available to an online Fabry disease support group. Respondents' results were compared with normative data for each questionnaire. The Fabry group described increased difficulty with various communication tasks when compared with the non-Fabry group.

Fabry disease - cochlear implants - X-linked disorder - peripheral neuropathy - lysosomal storage disease - enzyme substitution - enzyme replacement therapy

REFERENCES

• 1 Vibert D, Blaser B, Ozdoba C et al.. Fabry's disease: otoneurologic findings in twelve members of one family.  Ann Otol Rhinol Laryngol Suppl. 2006;  115 412-418
• 2 Opitz J M, Stiles F C, Wise D et al.. The genetics of angiokeratoma corporis diffusum (Fabry's disease) and its linkage relations with the Xg locus.  Am J Hum Genet. 1965;  17 325-342
• 3 Hoffmann B, Mayatepek E. Fabry disease—often seen, rarely diagnosed.  Dtsch Arztebl Int. 2009;  106 440-447
• 4 Eng C M, Germain D P, Banikazemi M et al.. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement.  Genet Med. 2006;  8 539-548
• 5 Winchester B, Vellodi A, Young E. The molecular basis of lysosomal storage diseases and their treatment.  Biochem Soc Trans. 2000;  28 150-154
• 6 MacDermot K D, Holmes A, Miners A H. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males.  J Med Genet. 2001;  38 750-760
• 7 Clarke J TR. Narrative review: Fabry disease.  Ann Intern Med. 2007;  146 425-433
• 8 Meikle P J, Hopwood J J, Clague A E, Carey W F. Prevalence of lysosomal storage disorders.  JAMA. 1999;  281 249-254
• 9 MacDermot K D, Holmes A, Miners A H. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females.  J Med Genet. 2001;  38 769-775
• 10 Callegaro D, Kaimen-Maciel D R. Fabry's disease as a differential diagnosis of MS.  Int MS J. 2006;  13 27-30
• 11 Xu J, Kochanek K D, Murphy S L, Tejada-Vera B. Division of Vital Statistics; Deaths: final data for 2007.  Natl Vital Stat Rep. 2010;  58 1-73
• 12 Germain D P, Avan P, Chassaing A, Bonfils P. Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients.  BMC Med Genet. 2002;  3 1-10
• 13 Conti G, Sergi B. Auditory and vestibular findings in Fabry disease: a study of hemizygous males and heterozygous females.  Acta Paediatr Suppl. 2003;  92 33-37; discussion 27
• 14 Sakurai Y, Kojima H, Shiwa M, Ohashi T, Eto Y, Moriyama H. The hearing status in 12 female and 15 male Japanese Fabry patients.  Auris Nasus Larynx. 2009;  36 627-632
• 15 Hegemann S, Hajioff D, Conti G et al.. Hearing loss in Fabry disease: data from the Fabry Outcome Survey.  Eur J Clin Invest. 2006;  36 654-662
• 16 Martins A M, D'Almeida V, Kyosen S O et al.. Guidelines to diagnosis and monitoring of Fabry disease and review of treatment experiences.  J Pediatr. 2009;  155 (4, Suppl) S19-S31
• 17 Palla A, Hegemann S, Widmer U, Straumann D. Vestibular and auditory deficits in Fabry disease and their response to enzyme replacement therapy.  J Neurol. 2007;  254 1433-1442
• 18 Schachern P A, Shea D A, Paparella M M, Yoon T H. Otologic histopathology of Fabry's disease.  Ann Otol Rhinol Laryngol. 1989;  98 (5 Pt 1) 359-363
• 19 Frantz M C, Pontz B F, Arnold W. Hyperbaric oxygen treatment restores sudden hearing loss in a patient with Fabry disease.  ORL J Otorhinolaryngol Relat Spec. 2008;  70 210-213
• 20 Choi J H, Cho Y M, Suh K S et al.. Short-term efficacy of enzyme replacement therapy in Korean patients with Fabry disease.  J Korean Med Sci. 2008;  23 243-250
• 21 Hajioff D, Enever Y, Quiney R, Zuckerman J, Mackermot K, Mehta A. Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy.  J Inherit Metab Dis. 2003;  26 787-794
• 22 Peterson G E, Lehiste I. Revised CNC lists for auditory tests.  J Speech Hear Disord. 1962;  27 62-70
• 23 Nilsson M, Soli S D, Sullivan J A. Development of the Hearing in Noise Test for the measurement of speech reception thresholds in quiet and in noise.  J Acoust Soc Am. 1994;  95 1085-1099
• 24 Spahr A J, Dorman M F. Effects of minimum stimulation settings for the Med El Tempo + speech processor on speech understanding.  Ear Hear. 2005;  26 (4, Suppl) 2S-6S
• 25 Bench J, Kowal A, Bamford J. The BKB (Bamford-Kowal-Bench) sentence lists for partially-hearing children.  Br J Audiol. 1979;  13 108-112
• 26 Etymotic Research .Bamford-Kowal-Bench Speech-in-Noise Test (Version 1.03) [Audio CD]. Elk Grove Village, IL: Author; 2005
• 27 Cox R M, Alexander G C. The abbreviated profile of hearing aid benefit.  Ear Hear. 1995;  16 176-186
• 28 Jacobson G P, Newman C W. The development of the Dizziness Handicap Inventory.  Arch Otolaryngol Head Neck Surg. 1990;  116 424-427